Insightful Word
  • Investing
  • Stock
  • Economy
  • Politics
  • Investing
  • Stock
  • Economy
  • Politics
No Result
View All Result
Insightful Word
No Result
View All Result
Home Stock

Evolus shares surge on strong Q4 results and upbeat 2025 outlook

admin by admin
January 21, 2025
in Stock
0
Evolus shares surge on strong Q4 results and upbeat 2025 outlook
0
SHARES
8
VIEWS
Share on FacebookShare on Twitter

Investing.com — Evolus, Inc. (NASDAQ: NASDAQ:EOLS) stock rose 17% following the company’s announcement of preliminary unaudited fourth quarter and full-year 2024 net revenue, along with its guidance for 2025 that surpassed market expectations.

The aesthetic portfolio company reported a 30% increase in fourth quarter net revenues compared to the same period last year, reaching $79.0 million, which exceeded the consensus forecast of $77 million. Full-year net revenues for 2024 climbed to $266.3 million, marking a 32% growth over the previous year and hitting the upper end of the company’s guidance range.

Evolus attributed the robust performance to significant market share gains, particularly with its flagship neurotoxin product, Jeuveau®, in the U.S. market, and the international expansion of Nuceiva®. The company’s CEO, David Moatazedi, highlighted consistent revenue growth over the past five years, attributing it to the company’s effective business model and performance beauty approach.

The company also provided an optimistic outlook for 2025, estimating total net revenues to be between $345 million and $355 million, which would represent a 30% to 33% increase from 2024’s preliminary results. This guidance is above the consensus estimate of $352 million for FY25. The anticipated growth is partly due to the expected contributions from the upcoming launch of Evolysse and Estyme® injectable HA gels, which are projected to account for 8-10% of total revenue for the year.

Moreover, Evolus expects to achieve positive non-GAAP operating income for the full year of 2025, with significant growth projected for the fourth quarter following the launch of their new products. The company also reported an increase in cash and cash equivalents, highlighting strong sales growth, cash collections, and prudent expense management.

The market’s positive reaction to Evolus’ earnings and guidance reflects investor confidence in the company’s growth trajectory and its ability to capitalize on its expanding product portfolio. With the FDA approval for Evolysse injectable HA gels expected within the next 90 days and a U.S. launch planned for the second quarter of 2025, Evolus is poised to transition from a single product company to a multi-product innovator in the performance beauty space.

This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

This post appeared first on investing.com

Previous Post

Deutsche Bank lifts rating on General Motor to ‘buy’

Next Post

Google adds SandboxAQ’s quantitative AI models to cloud offerings

admin

admin

Next Post
Google adds SandboxAQ’s quantitative AI models to cloud offerings

Google adds SandboxAQ’s quantitative AI models to cloud offerings

Trending News

How Leonard Lauder turned Estée Lauder from a family firm into a global powerhouse

How Leonard Lauder turned Estée Lauder from a family firm into a global powerhouse

June 16, 2025
JPMorgan breaks down 2 paths for the US economy in 2025

JPMorgan breaks down 2 paths for the US economy in 2025

November 24, 2024
Dow plunges over 2,000 points as China slaps retaliatory tariffs, tech stocks lead Wall Street meltdown

Dow plunges over 2,000 points as China slaps retaliatory tariffs, tech stocks lead Wall Street meltdown

April 5, 2025
Subscribe to Insightful Word


    Recent News

    Dow futures soar 250 points today: 5 things to know before Wall Street opens

    Dow futures soar 250 points today: 5 things to know before Wall Street opens

    August 7, 2025
    Affirm stock price is rising: is it a buy before earnings?

    Affirm stock price is rising: is it a buy before earnings?

    August 7, 2025
    Intel stock plunges sharply after Trump calls on CEO to resign: here’s why rebound may take time

    Intel stock plunges sharply after Trump calls on CEO to resign: here’s why rebound may take time

    August 7, 2025
    Goldman Sachs boosts Nvidia price target to $200 ahead of Q2 earnings

    Goldman Sachs boosts Nvidia price target to $200 ahead of Q2 earnings

    August 7, 2025

    Recent News

    Dow futures soar 250 points today: 5 things to know before Wall Street opens

    Dow futures soar 250 points today: 5 things to know before Wall Street opens

    August 7, 2025
    Affirm stock price is rising: is it a buy before earnings?

    Affirm stock price is rising: is it a buy before earnings?

    August 7, 2025

    Latest News

    • Dow futures soar 250 points today: 5 things to know before Wall Street opens
    • Affirm stock price is rising: is it a buy before earnings?
    • Intel stock plunges sharply after Trump calls on CEO to resign: here’s why rebound may take time

    About Insightful Word

    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools
    • Contacts
    • Cookie Notice
    • Privacy Policy
    • Terms of Service
    • Trading tools

    Copyright © 2025 Insightfulword.com. All Rights Reserved.

    No Result
    View All Result
    • Investing
    • Stock
    • Economy
    • Politics

    Copyright © 2025 Insightfulword.com. All Rights Reserved.